吡柔比星预防浅表性膀胱癌术后复发的疗效观察  

Pirarubicin Preventive Efficacy of Superficial Bladder Cancer Recurrence

作　　者：张鑫[1] 安瑞华[1] 于净松[1] 于时良[1] 甘秀国[1] 

机构地区：[1]哈尔滨医科大学附属第一医院泌尿外科一科,黑龙江哈尔滨150000

出　　处：《现代生物医学进展》2015年第28期5496-5499,共4页Progress in Modern Biomedicine

摘　　要：目的:比较吡柔比星与吉西他滨膀胱内灌注预防浅表性膀胱癌术后复发的疗效。方法:40例浅表性膀胱癌患者根据随机抽签法分为治疗组与对照组各20例,所有患者都采用经尿道膀胱肿瘤电切方法,对照组用吉西他滨,治疗组用吡柔比星进行膀胱灌注,比较两组患者术后复发率的不同。结果:所有患者都完成治疗,随访1年,治疗组的复发率为5.0%,对照组为25.0%,治疗组的复发率明显低于对照组,对比差异明显,有统计学意义(P<0.05)。经过观察,治疗组的膀胱刺激症状、骨髓抑制、尿道狭窄等不良反应总体发生率明显少于对照组,两者比较有统计学意义(P<0.05)。结论:相对于吉西他滨,吡柔比星膀胱内灌注预防浅表性膀胱癌术后复发有很好的效果,不良反应少,在临床上需要根据患者的实际情况来选择不同的灌注药物。Objective： To compare Pirarubicin efficacy with gemcitabine chemotherapy for preventing recurrence of superficial bladder cancer, bladder within the foreshore him. Methods： 40 cases of patients with superficial bladder cancer based on randomly divided into treatment group and control group 20 cases, all patients using transurethral bladder tumor transurethral approach, the control group was treated with gemcitabine treatment group were Pirarubicinintravesical different recurrence rate of two groups were compared.Results： All patients completed treatment, follow-up of 1 year, the treatment group, the recurrence rate was 5.0%, the control group was25.0%, the recurrence rate of the treatment group was significantly lower than the control group, compared to obvious differences were statistically significant（P〈0.05）. Through observation, bladder irritation treatment group, bone marrow suppression, urethral stricture overall incidence of adverse reactions was significantly less than the control group, both statistically significant（P〈0.05）. Conclusion：Compared with gemcitabine, the Star THP intravesical prevention of recurrence of superficial bladder cancer have a good effect, fewer adverse reactions, in accordance with the actual situation on the clinical needs of patients to choose a different infusion drugs.

关 键 词：吡柔比星 吉西他滨 膀胱内灌注 浅表性膀胱癌 复发 

分 类 号：R737.14[医药卫生—肿瘤]